Bruce Carleton
Papers
1
Total Citations
18
H-Index
1
About
Dr. Bruce Carleton is a pioneering researcher in pediatric clinical pharmacology and pharmacogenomics, with a primary focus on understanding and preventing adverse drug reactions in children. His seminal work, "Medication Errors: Neonates, Infants and Children Are the Most Vulnerable!" (2008, 18 citations), established a foundational framework for recognizing the heightened susceptibility of pediatric populations to medication errors and adverse drug events. Dr. Carleton's major contributions include identifying genetic biomarkers that predict severe adverse drug reactions, particularly in children undergoing cancer treatment, and developing clinical decision-support tools to personalize medication dosing. His research has demonstrated that up to 93% of medication errors in children are preventable, fundamentally changing how healthcare systems approach pediatric pharmacovigilance. As a leader in the Canadian Pharmacogenomics Network for Drug Safety, Dr. Carleton has translated genomic discoveries into actionable clinical guidelines, directly impacting patient safety. His work has been instrumental in reducing life-threatening adverse events in vulnerable populations, earning him international recognition as a champion for safer pediatric pharmacotherapy.
Research Focus
Key Achievements
Top Papers
- 1Medication Errors: Neonates, Infants and Children Are the Most Vulnerable!18 citations · 2008